Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

5.7%

118 terminated/withdrawn out of 2080 trials

Success Rate

91.1%

+4.6% vs industry average

Late-Stage Pipeline

4%

91 trials in Phase 3/4

Results Transparency

35%

425 of 1201 completed trials have results

Key Signals

324 recruiting425 with results77 terminated41 withdrawn

Enrollment Performance

Analytics

Phase 2
675(42.1%)
Phase 1
463(28.8%)
N/A
336(20.9%)
Phase 3
81(5.0%)
Early Phase 1
40(2.5%)
Phase 4
10(0.6%)
1605Total
Phase 2(675)
Phase 1(463)
N/A(336)
Phase 3(81)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (2080)

Showing 20 of 2080 trials
NCT05640843Not ApplicableRecruiting

A Study Comparing a Plant-Based Diet With Supplements and Placebo in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)

Role: lead

NCT00466531Phase 1Active Not Recruiting

Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19

Role: lead

NCT04552288Phase 2Active Not Recruiting

Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies

Role: lead

NCT06347705Phase 2Recruiting

A Study of 2141-V11 in Combination With Standard Treatments in People With Prostate Cancer

Role: lead

NCT06083922Phase 2Recruiting

A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)

Role: lead

NCT05789485Phase 2Recruiting

A Study on the Effects of Exercise on Side Effects From Treatment for Gastrointestinal Cancers

Role: lead

NCT03377387Phase 1Active Not Recruiting

Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer

Role: lead

NCT07303894Phase 2Recruiting

A Study of Isoquercetin in People With Ovarian Cancer

Role: lead

NCT07532902Phase 1Recruiting

A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer

Role: lead

NCT03618550Phase 2Recruiting

Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

Role: lead

NCT06935071Active Not Recruiting

Endoprosthetic Replacement for Pathological Fractures of the Hip: A 35-year Update

Role: lead

NCT05534438Phase 2Recruiting

A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer

Role: lead

NCT03133650Phase 1Active Not Recruiting

A Trial of a New Type of Photodynamic Therapy (VTP) in the Treatment of Patients With Cancer of the Esophagus Who Have Trouble Swallowing

Role: lead

NCT04452825Not ApplicableRecruiting

A New Psychotherapy Intervention for Older Cancer Patients

Role: lead

NCT06066333Phase 2Recruiting

Study of Radiotherapy and Pembrolizumab in People With Adrenocortical Carcinoma

Role: lead

NCT07144800Not ApplicableRecruiting

Family COMIDA (Consumo de Opciones Más Ideales De Alimentos) (Eating More Ideal Food Options)

Role: lead

NCT07111507Phase 2Recruiting

A Study of Tarlatamab for People With Prostate Cancer

Role: lead

NCT07249528Not ApplicableNot Yet Recruiting

A Study of Voice as a Way to Monitor for Side Effects in People Receiving CAR T-Cell Therapy

Role: lead

NCT04208490Not ApplicableActive Not Recruiting

Implementation and Effectiveness Trial of HN-STAR

Role: collaborator

NCT03684980Early Phase 1Active Not Recruiting

LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma

Role: lead